NuVasive to acquire Osiris unit

05/8/2008 | Houston Chronicle (tiered subscription model)

NuVasive will purchase Osteocol, a subsidiary of Osiris Therapeutics, in a deal that allows it to gain access to the unit's developing stem cell technology and expand into the biotech market. The acquisition, which will close in the third quarter, includes $35 million in cash and future milestone payments to Osiris worth up to $50 million.

View Full Article in:

Houston Chronicle (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI